Acasti pharma inc. retains lytham partners to lead strategic investor relations and shareholder communication program

Laval, qc , may 23, 2022 /prnewswire/ -- acasti pharma inc. (nasdaq: acst and tsx-v: acst) ("acasti"; the "company"), a late-stage specialty pharmaceutical company with drug delivery technologies and drug candidates addressing rare and orphan diseases, has retained one of the industry's leading investor relations firms, lytham partners, llc, to lead a strategic investor relations and shareholder communication program. for more than 20 years, lytham partners has created a highly diverse network of institutional investors, while creating a framework of best practices in all aspects of corporate and shareholder communications.
ACST Ratings Summary
ACST Quant Ranking